

MBS Antibiogram 2022

| GRAM NEGATIVE | | ANTIBIOTICS | | | | | | | | | | | | | | |
|-------------------------------|---------------------|-----------------------------|------------|-----------|----------|-------------|---------------|-----------|------------|--------------|-----------|----------------|-------------------------|--------------|------------|---------------|
| 1/1/2022-12/31/2022 | Number tested | Amoxicillin/Clavulanic Acid | Ampicillin | Cefazolin | Cefepime | Ceftriaxone | Ciprofloxacin | Ertapenem | Gentamicin | Levofloxacin | Meropenem | Nitrofurantoin | Piperacillin/Tazobactam | Tetracycline | Tobramycin | Trimeth/Sulfa |
| ORGANISM | PERCENT SUSCEPTIBLE | | | | | | | | | | | | | | | |
| <i>Escherichia coli</i> | 531 | 85 | 54 | 88 | 97 | 95 | 79 | 100 | 94 | 76 | 100 | 96 | 98 | 82 | 93 | 82 |
| <i>Klebsiella pneumoniae</i> | 57 | 93 | 0 | 89 | 93 | 91 | 91 | 100 | 98 | 89 | 100 | 35 | 96 | 88 | 96 | 88 |
| <i>Proteus mirabilis</i> | 60 | 87 | 50 | 85 | 93 | 93 | 48 | 100 | 88 | 48 | 100 | 0 | 100 | 0 | 90 | 47 |
| <i>Pseudomonas aeruginosa</i> | 69 | | | | 99 | | 74 | | 94 | 70 | 94 | | 96 | | 100 | |

| GRAM POSITIVE | | ANTIBIOTICS | | | | | | | | | | |
|-----------------------------------|---------------------|-------------|-------------|--------------|-------------------------|-----------|----------------|-----------|---------------------------|--------------|---------------|------------|
| 1/1/2022-12/31/2022 | Number tested | Ampicillin | Clindamycin | Erythromycin | Gentamycin (High-Level) | Linezolid | Nitrofurantoin | Oxacillin | Streptomycin (High-Level) | Tetracycline | Trimeth/Sulfa | Vancomycin |
| Organism | PERCENT SUSCEPTIBLE | | | | | | | | | | | |
| <i>Enterococcus faecalis</i> | 51 | 100 | | 8 | 82 | 98 | 100 | | 84 | 35 | | 98 |
| <i>Staphylococcus aureus, ALL</i> | 220 | | 74 | 40 | | 100 | | 51 | | 77 | 89 | 100 |
| <i>MRSA only</i> | 109 | | 72 | 19 | | 100 | | 0 | | 76 | 79 | 100 |
| <i>MSSA only</i> | 111 | | 78 | 62 | | 100 | | 100 | | 78 | 99 | 100 |
| <i>Staphylococcus epidermidis</i> | 30 | | 60 | 37 | | 100 | | 47 | | 80 | 50 | 97 |


- 85-100% Susceptible
- 60-84% Susceptible
- <60% Susceptible
- Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated
- Shaded boxes indicate organism/antimicrobial combinates not tested routinely
- Denotes manufacturer reporting limitation

2021 vs. 2022 MBS Antibiograms

| GRAM NEGATIVE | | ANTIBIOTICS | | | | | | | | | | | | | | | |
|---------------|-------------------------------|---------------|-----------------------------|------------|-----------|----------|-------------|---------------|-----------|------------|--------------|-----------|----------------|-------------------------|--------------|------------|---------------|
| | | Number tested | Amoxicillin/Clavulanic Acid | Ampicillin | Cefazolin | Cefepime | Ceftriaxone | Ciprofloxacin | Ertapenem | Gentamicin | Levofloxacin | Meropenem | Nitrofurantoin | Piperacillin/Tazobactam | Tetracycline | Tobramycin | Trimeth/Sulfa |
| | | | PERCENT SUSCEPTIBLE | | | | | | | | | | | | | | |
| 2021 | <i>Escherichia coli</i> | 507 | 87 | 56 | 88 | 98 | 97 | 78 | 100 | 95 | 75 | 100 | 97 | 97 | 82 | 95 | 78 |
| 2022 | <i>Escherichia coli</i> | 531 | 85 | 54 | 88 | 97 | 95 | 79 | 100 | 94 | 76 | 100 | 96 | 98 | 82 | 93 | 82 |
| 2021 | <i>Klebsiella pneumoniae</i> | 65 | 100 | 0 | 97 | 100 | 100 | 91 | 98 | 100 | 89 | 98 | 22 | 97 | 86 | 100 | 94 |
| 2022 | <i>Klebsiella pneumoniae</i> | 57 | 93 | 0 | 89 | 93 | 91 | 91 | 100 | 98 | 89 | 100 | 35 | 96 | 88 | 96 | 88 |
| 2021 | <i>Proteus mirabilis</i> | 35 | 94 | 74 | 89 | 97 | 94 | 63 | 100 | 94 | 66 | 100 | 0 | 100 | 0 | 94 | 74 |
| 2022 | <i>Proteus mirabilis</i> | 60 | 87 | 50 | 85 | 93 | 93 | 48 | 100 | 88 | 48 | 100 | 0 | 100 | 0 | 90 | 47 |
| 2021 | <i>Pseudomonas aeruginosa</i> | 62 | | | | 97 | | 87 | | 95 | 82 | 97 | | 94 | | 97 | |
| 2022 | <i>Pseudomonas aeruginosa</i> | 69 | | | | 99 | | 74 | | 94 | 70 | 94 | | 96 | | 100 | |

| GRAM POSITIVE | | ANTIBIOTICS | | | | | | | | | | | | |
|---------------|-----------------------------------|---------------|---------------------|-------------|--------------|-------------------------|-----------|----------------|-----------|---------------------------|--------------|---------------|------------|--|
| | | Number tested | Ampicillin | Clindamycin | Erythromycin | Gentamycin (High-Level) | Linezolid | Nitrofurantoin | Oxacillin | Streptomycin (High-Level) | Tetracycline | Trimeth/Sulfa | Vancomycin | |
| | | | PERCENT SUSCEPTIBLE | | | | | | | | | | | |
| 2021 | <i>Enterococcus faecalis</i> | 50 | 100 | | 10 | 80 | 94 | 100 | | 80 | 36 | | 96 | |
| 2022 | <i>Enterococcus faecalis</i> | 51 | 100 | | 8 | 82 | 98 | 100 | | 84 | 35 | | 98 | |
| 2021 | <i>Staphylococcus aureus, ALL</i> | 153 | | 71 | 40 | | 100 | | 58 | | 86 | 92 | 100 | |
| 2022 | <i>Staphylococcus aureus, ALL</i> | 220 | | 74 | 40 | | 100 | | 51 | | 77 | 89 | 100 | |
| 2021 | <i>MRSA only</i> | 66 | | 57 | 14 | | 100 | | 0 | | 83 | 83 | 100 | |
| 2022 | <i>MRSA only</i> | 109 | | 72 | 19 | | 100 | | 0 | | 76 | 79 | 100 | |
| 2021 | <i>MSSA only</i> | 87 | | 82 | 59 | | 100 | | 100 | | 87 | 100 | 100 | |
| 2022 | <i>MSSA only</i> | 111 | | 78 | 62 | | 100 | | 100 | | 78 | 99 | 100 | |
| 2021 | <i>Staphylococcus epidermidis</i> | 30 | | 60 | 20 | | 100 | | 47 | | 70 | 63 | 100 | |
| 2022 | <i>Staphylococcus epidermidis</i> | 30 | | 60 | 37 | | 100 | | 47 | | 80 | 50 | 97 | |

- 85-100% Susceptible
- 60-84% Susceptible
- <60% Susceptible
- Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated
- Shaded boxes indicate organism/antimicrobial combines not tested routinely

 Denotes manufacturer reporting limitation